{
    "root": "2f264a4e-8ad8-ec12-e063-6394a90ad965",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Loxapine",
    "value": "20250227",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLACRILIN POTASSIUM",
            "code": "0BZ5A00FQU"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "METHYL ALCOHOL",
            "code": "Y4S76JWI15"
        },
        {
            "name": "LOXAPINE SUCCINATE",
            "code": "X59SG0MRYU"
        }
    ],
    "indications": "loxapine capsules , usp indicated treatment schizophrenia . efficacy loxapine schizophrenia established enrolled newly hospitalized chronically hospitalized acutely ill schizophrenic patients subjects .",
    "contraindications": "loxapine capsules , usp administered , usually divided doses , two four times day . daily ( terms base equivalents ) adjusted individual patient 's needs assessed severity symptoms previous history response antipsychotic drugs .",
    "warningsAndPrecautions": "loxapine capsules , usp available following strengths : loxapine succinate , usp 34.0 mg equivalent 25 mg loxapine , light green opaque body dark green opaque cap , imprinted logo `` lannett `` cap `` 1396 `` body supplied follows : ndc : 70518-1896-00 ndc : 70518-1896-01 ndc : 70518-1896-02 packaging : 30 1 blister pack packaging : 100 1 box packaging : 1 1 pouch store 20\u00b0-25\u00b0c ( 68\u00b0-77\u00b0f ) . [ usp controlled room temperature . ] dispense tight , child-resistant container . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "loxapine contraindicated comatose severe drug-induced depressed states ( alcohol , barbiturates , narcotics , etc . ) . loxapine contraindicated individuals known hypersensitivity dibenzoxazepines .",
    "indications_original": "Loxapine Capsules, USP are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.",
    "contraindications_original": "Loxapine Capsules, USP are administered, usually in divided doses, two to four times a day. Daily dosage (in terms of base equivalents) should be adjusted to the individual patient's needs as assessed by the severity of symptoms and previous history of response to antipsychotic drugs.",
    "warningsAndPrecautions_original": "Loxapine Capsules, USP are available in the following strengths:\n                  Loxapine Succinate, USP 34.0 mg equivalent to 25 mg loxapine, light green opaque body and dark green opaque cap, imprinted with logo \"LANNETT\" on the cap and \"1396\" on the body are supplied as follows:\n                  \n                  NDC: 70518-1896-00\n                  NDC: 70518-1896-01\n                  NDC: 70518-1896-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store at 20\u00b0-25\u00b0C (68\u00b0-77\u00b0F). [See USP controlled room temperature.] Dispense in a tight, child-resistant container.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Loxapine is contraindicated in comatose or severe drug-induced depressed states (alcohol, barbiturates, narcotics, etc.).\n                  Loxapine is contraindicated in individuals with known hypersensitivity to dibenzoxazepines."
}